Invitrogen Herceptin candidate Dx launches
This article was originally published in The Gray Sheet
Executive Summary
Firm taps Biocare Medical to distribute its SPOT-Light HER2 test. The kit was PMA approved July 8 for use as an aid to assess which breast cancer patients might benefit from treatment with Genentech's Herceptin therapy (1"The Gray Sheet" July 14, 2008, p. 17). "Working with the Biocare sales force, we believe we will be able to more rapidly and efficiently deliver this critical diagnostic," Invitrogen said
You may also be interested in...
Invitrogen: New Herceptin Candidate Dx Gives More Labs A Chance To Test
Invitrogen's SPOT-Light HER2 test, PMA-approved by FDA July 8, will not be the first kit in the U.S. to help physicians decide if a breast cancer patient will benefit from Genentech's Herceptin therapy, but it will allow a host of new laboratories to perform the analysis, according to the firm
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.